Neoadjuvant Nab-Paclitaxel in Breast Cancer: Trial Results and Patient Care

The link between the achievement of pCR and the long-term clinical benefit was supported by findings of a pooled analysis, with the greatest prognostic value observed in aggressive tumor subtypes.

 The Lancet Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.